Also trades as: AMEUF (OTC) · $vol 0M
AVR.AX ASX
Anteris Technologies Ltd
1W: +3.8%
1M: -7.0%
3M: -27.4%
YTD: +42.7%
1Y: +88.1%
3Y: -47.1%
5Y: +30.4%
A$11.17 ($7.77)
+0.15 (+1.36%)
Weekly Expected Move ±4.9%
A$10
A$11
A$11
A$12
A$12
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market CapA$1.1B ($751.3M)
52W Range5.2-15.47
Volume1,748
Avg Volume16,984
Beta0.73
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOWayne Geoffrey Paterson
Employees174
SectorHealthcare
IndustryMedical - Devices
IPO Date2004-03-22
Websiteanteristech.com
Toowong Tower, Level 3, Suite 302, 9 Sherwood Road
Toowong, QLD 4066
AU
Toowong, QLD 4066
AU
61 13 0055 0310
About Anteris Technologies Ltd
Anteris Technologies Ltd is a firm specializing in the structural heart domain. It is responsible for the production and distribution of ADAPT, a product based on regenerative tissue technology. The company is also actively involved in advancing DurAVRâ¢, an innovative 3D single-component aortic valve specifically designed for treating aortic stenosis. Additionally, Anteris allocates resources to the research and development of regenerative medicines. Founded in 1999, the enterprise was formerly known as Admedus Limited until it rebranded to Anteris Technologies Ltd in May 2020. Its primary operations are conducted from its base in Toowong, Australia.
Latest News
No recent news
Recent Insider Trades
No insider trades found